<DOC>
	<DOCNO>NCT00774995</DOCNO>
	<brief_summary>This study evaluate immune response healthy subject receive neonatal vaccination course GSK Biologicals ' Engerix™-B vaccine , approximately 20 year ago . The presence immune memory hepatitis B surface antigen ( HBsAg ) subject investigated administration challenge dose hepatitis B vaccine comparison antibody concentration one month vaccination . This protocol post deal objective &amp; outcome measure booster phase . No new subject recruit booster phase study .</brief_summary>
	<brief_title>Immune Response Healthy Subjects Who Received Neonatal Vaccination Course With Engerix™-B Vaccine .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A male female receive complete neonatal primary vaccination course Engerix™B 103860/273 primary study approximately 20 year earlier . AntiHBs antibody concentration less specify value last available followup timepoint . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . If subject female , must nonchildbearing potential , childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede Engerix™B challenge dose , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior challenge dose administration . Planned administration/ administration vaccine foreseen study protocol start 30 day challenge dose end 30 day . Administration hepatitis B vaccine outside context study followup timepoint antiHBs antibody concentration less specified value current challenge dose study visit . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product History allergic disease reaction likely exacerbate component vaccine . Acute disease time enrolment . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Administration immunoglobulins and/or blood product within three month precede challenge dose visit plan administration study period . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Engerix-B</keyword>
	<keyword>Hepatitis B</keyword>
</DOC>